Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

著者: Brian G. Feagan, Bruce E. Sands, William J. Sandborn, Matthew Germinaro, Marion Vetter, Jie Shao, Shihong Sheng, Jewel Johanns, Julián Panés, Tkachev Av, Dilara Kalimullina, Robert Petryka, М. Ф. Осипенко, Nataliia Tsarynna, Leonid Bilіanskyi, D Kleczkowski, Andrii Yurkiv, Marek Woynarowski, О. Аbrahamovych, Olha Ivanishyn, Grażyna Rydzewska, Jarosław Kierkuś, Elina Petrova, Olga Vasilevskaya, Halyna Afanasieva, Carlos Fernando de Magalhães Francesconi, Jarosław Leszczyszyn, Elena Bunkova, Dmitry Platonov, Olena Datsenko, Oleksii Gridnyev, Ihor Hospodarsky, Liudmyla Nykodymivna Prystupa, Mykola Stanislavchuk, Anatoly Pershko, О. Б. Щукина, В. И. Симаненков, Oleksandr Golovchenko, William Holderman, Juan S. Lasa, Jakob Begun, Maria de Lourdes de Abreu Ferrari, Pedro López, A. A. Obrezan, Shiraz Farooq, Felix Tiongco, Abel Novillo, Emiliano Tron, Finlay Macrae, Rupert W. Leong, Lígia Yukie Sassaki, Cyrla Zaltman, Roberto Luiz Kaiser, Andreas Stallmach, Jochen Klaus, Manuel Martı́nez, Azalia Ruiz, Р А Абдулхаков, Vishvinder Sharma, Louis Y Korman, James D. Lord, Bhaktasharan Patel, Timothy E. Ritter - The Lancet 2023 被引用: 224